Adaptive dosing of high‐dose busulfan in real‐world adult patients undergoing haematopoietic cell transplant conditioning
British Journal of Clinical Pharmacology · 2025
DOI: 10.1111/bcp.16343 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Dorian Protzenko und 6 weiteren Autor:innen. Beteiligte Einrichtung: COMPO, Inserm U1068 Centre de Recherche en Cancérologie de Marseille, Aix Marseille University, Marseille, France. Hauptthemen laut MEDLINE: Busulfan, Hematopoietic Stem Cell Transplantation, Transplantation Conditioning, Immunosuppressive Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Aim
To evaluate the effectiveness of a Bayesian adaptive dosing strategy in achieving target busulfan exposure in adult patients undergoing haematopoietic cell transplantation (HCT).
Methods
This study included 71 adult patients scheduled to receive high‐dose busulfan. Busulfan was administered to achieve a cumulative area under the curve (AUC) of 66.0 mg.h/L (16 000 μM.min), 82.60 mg.h/L (20 000 μM.min) or 87.6 mg.h/L (21 200 μM.min) depending on the regimen. Individual pharmacokinetic (PK) parameters of busulfan were estimated from three blood samples using a one‐compartment model and Bayesian estimation after the first standard dose. Individual PK parameters were used to adjust subsequent doses to achieve the target exposure.
Results
All patients had their dose adjusted after the first dose administration. The final deviation from the target AUC was significantly improved compared to the initial deviation after standard mg/kg dosing (mean absolute deviation 19.5% vs 11.7%, P < .01). In addition, the proportion of patients with marked deviation from target exposure (ie, >25%) decreased significantly from 31% after standard dosing to 10% after PK‐guided dosing ( P < .01). Canonical busulfan‐related toxicity, specifically veno‐occlusive disease, was observed in 5% of patients who achieved successful PK‐guided dosing. In contrast, one‐third of patients with off‐target exposure with poor dosing experienced toxicity.
Conclusion
The Bayesian adaptive dosing strategy significantly improves the accuracy of achieving the target busulfan AUC in patients undergoing HCT. This approach not only reduces marked deviations from target exposure, but also reduces the incidence of busulfan‐related toxicity, thereby maintaining a favourable toxicity/efficacy ratio.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- COMPO, Inserm U1068 Centre de Recherche en Cancérologie de Marseille, Aix Marseille University, Marseille, France.
- HematologyDepartment, Paoli Calmettes Institute, Marseille, France.
- PRISM Platform, Biogénopôle, La Timone University Hospital of Marseille APHM, Marseille, France.
- OHIO, Inserm U1068 Centre de Recherche en Cancérologie de Marseille, Aix Marseille University, Marseille, France.
ORCID-Profile: Joseph Ciccolini
Zitieren
APA
Protzenko, D., Bouchacourt, B., Carriat, L., Maroselli, P., Boéri, C., Devillier, R., & Ciccolini, J. (2025). Adaptive dosing of high‐dose busulfan in real‐world adult patients undergoing haematopoietic cell transplant conditioning. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.16343
Vancouver
Protzenko D, Bouchacourt B, Carriat L, Maroselli P, Boéri C, Devillier R, et al. Adaptive dosing of high‐dose busulfan in real‐world adult patients undergoing haematopoietic cell transplant conditioning. British Journal of Clinical Pharmacology. 2025. doi:10.1111/bcp.16343
BibTeX
@article{Protzenko2025,
author = {Protzenko, Dorian and Bouchacourt, Benjamin and Carriat, Laure and Maroselli, Paul and Boéri, Clara and Devillier, Raynier and Ciccolini, Joseph},
title = {Adaptive dosing of high‐dose busulfan in real‐world adult patients undergoing haematopoietic cell transplant conditioning},
journal = {British Journal of Clinical Pharmacology},
year = {2025},
doi = {10.1111/bcp.16343}
}
EUVIMED